A meta-analysis and systematic review that attempted to compare responses to PARP inhibitors between germline and somatic BRCA1/BRCA2 mutations across cancer types concluded that the drugs appear to be equally effective but noted heterogeneity and possible publication bias [60]. The gene discussed is BRCA1; the disease is cancer.